Hannah Hershoff MD, PhD, has joined AiViva BioPharma as Chief Medical Officer

Newport Beach, California – September 1, 2022 – AiViva Biopharma, a clinical stage biopharmaceutical company, today announced it has appointed Hannah Hershoff, M.D., Ph.D. as its Chief Medical Officer. In this new role, Dr. Hershoff will provide leadership and direction to Clinical Strategy, Clinical Operations, Medical Affairs, Clinical Sciences, Data Management/Biometrics, and Drug Safety.

Dr. Hershoff is a trained neuro-ophthalmologist and eye surgeon and has over 30 years of clinical, development, and new drug development experience. She is coming to AiViva BioPharma from Longwood Pharmaceuticals, Inc. as their Chief Medical Officer. Prior experience includes President and Co-owner of MYAD Consulting Group, and Principal Investigator and Team Leader at the Novartis Institutes for BioMedical Research.

“Her breadth and scope in drug development, in a variety of therapeutics areas including ophthalmology will be a great addition to the AiViva management team.” said Diane Tang-Liu, Ph.D., CEO, President & Co-Founder.

Dr. Hershoff commented, “I am excited about being part of an experienced and dedicated team, focusing on developing focal therapies for therapeutic areas that have few options.”

Dr. Hershoff received her Doctor of Medicine at Jiangxi Medical School, China, her Ph.D. in Experimental Ophthalmology at Lund University, Sweden, and her MS at Sun Yat-Sen University, China.

About AiViva Biopharma, Inc.

AiViva is a clinical stage biopharmaceutical company led by a team of seasoned industry experts with proven track records in drug development and commercialization.  AiViva has developed innovative approaches to address high unmet medical needs by transforming treatment paradigms through focal therapies that target diseases of neovascularization, abnormal cell proliferation, and fibrosis.  Core competencies include development of novel drugs using proprietary technologies, including JEL™, in specialty therapeutic areas of dermatology, ophthalmology, urology and oncology.  Our lead products, AIV001 and AIV007, are designed to optimize therapeutic outcomes and lower treatment burden.